Expanding its global footprint in Latin America
Sterigenics International, a global provider of contract sterilisation, gamma technologies and medical isotopes, has acquired Brazilian sterilisation specialist Companhia Brasileira de Esterilização (CBE) for an undisclosed sum.
Founded in 1978, CBE was the first company to use gamma sterilisation methods in Brazil, and offers solutions through the largest particle accelerator (E-BEAM) in Latin America.
With the acquisition, Sterigencis will gain CBE's three manufacturing facilities, which have a total processing capacity of 12 million cubic feet, taking its total locations in Latin America to six.
Michael Mulhern, CEO of Sterigenics International, said: 'This strategic geographic acquisition demonstrates our commitment to expanding our global footprint in order to meet our customers’ growing needs.
'Going forward, we will continue investing in the future of Sterigenics and building upon our leadership position.'
In 2014, a Sterigenics affiliate acquired Nordion, the world’s largest provider of Cobalt-60, an isotope that produces gamma radiation and is a critical component of the gamma sterilisation process, creating the only vertically integrated sterilisation services company in the world.
Going forward, we will continue investing in the future of Sterigenics and building upon our leadership position
Additional acquisitions in 2014 included Florida-based gamma irradiation operator FTSI, as well as Gammarad, Italy’s leading gamma irradiation sterilisation company, which now serves as the company’s second gamma sterilisation facility in Western Europe.
Sterigenics operates 47 facilities in 13 countries across the Americas, Europe and Asia, providing contract sterilisation and ionisation services for the medical device, pharmaceutical, food safety, and high-performance materials industries.
Through its SteriPro Labs service, Sterigenics offers microbiological and analytical testing and consultancy to assist customers in developing and maintaining sterilisation solutions in medical devices, tissue/implantable products, and pharmaceuticals and biologics fields.
Sterigenics is owned by private equity firms Warburg Pincus and GTCR.